Veru Presents New Results at ObesityWeek 2026: GLP-1 Weight Loss in Older Adults Associated with Physical Function Decline; Adding Enobosarm Preserved Significant Lean Mass and Physical Function
Globe Newswire•17/11/2026•08:30 ET
0
Key Highlights
- ➤Enobosarm preserved 100% of lean mass versus 2.0-kilogram loss with placebo at 16 weeks
- ➤Enobosarm cut slower stair-climb incidence to 12% versus 42% with placebo
- ➤No enobosarm patients had ≥10% stair-climb power decline versus 42% with placebo
- ➤PLATEAU enrolled 239 patients, with interim DXA analysis expected in calendar Q1 2027
- ➤New US patent protects enobosarm with semaglutide until late 2044
Expert Statements
Louis Aronne, Past president of the Obesity Society and Chief Medical Advisor to Veru
“Older patients with obesity represent a special population at risk for loss of lean mass and muscle function. It is encouraging and exciting to see that enobosarm as adjunctive therapy with GLP-1 RA drugs has the potential to preserve lean mass and physical function and improve the quality of weight loss in older patients being treated for obesity.”
Mitchell Steiner, Chairman, President, and Chief Executive Officer of Veru Inc.
“Based on the post hoc subset analysis from the Phase 2 QUALITY study, patients 65 and older with obesity appear to be the most at-risk patients for loss of absolute muscle mass with evidence of decline in physical function from weight reduction while receiving a GLP-1 RA drug. On the other hand, patients receiving enobosarm in combination with a GLP-1 RA preserved lean mass and prevented decline in physical function. These results support the selection of the patient population, patients who are 65 and older with obesity, in the ongoing Phase 2b PLATEAU study.”
Mitchell Steiner, Chairman, President, and Chief Executive Officer of Veru Inc.
“Our obesity program is on track. The Phase 2b PLATEAU clinical trial is fully enrolled, and we expect the interim analysis, a near term milestone, in calendar Q1 2027. We entered into a clinical supply agreement with Novo(1), and we now have an issued US patent for enobosarm with semaglutide with expiry in late 2044.”
-- In a post hoc analysis of patients ≥65 years from the positive Phase 2b QUALITY study, those on semaglutide + placebo lost significant lean mass and had reduced stair climb power and slower stair climb time at 16 weeks, despite significant weight loss --
--Adding enobosarm preserved lean mass and stair climb physical function in older patients ≥65 years with obesity receiving semaglutide--
Get started
Create a free account to read the full story.
